Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670159 | 1.00 | MEN1 (0.67) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL8012399 | 0.80 | MAPT (0.67) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL15305605 | 0.80 | MEN1 (0.67) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL28813132 | 0.80 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL8012401 | 0.80 | MAPT (0.67) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL29727412 | 0.79 | LMNA (0.70) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL28818211 | 0.79 | LMNA (0.70) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL14031533 | 0.78 | GSK3B (0.67) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL1358078 | 0.78 | GSK3B (0.67) | MEN1KMT2AMAPTKDM4EBLM | |
| SCHEMBL1358077 | 0.78 | GSK3B (0.67) | MEN1KMT2AMAPTKDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | MEN1 40/4885KMT2A 1114/4885MAPT 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.